Log In
Print this Print this

Metaglip, glipizide/metformin

  Manage Alerts
Collapse Summary General Information
Company Bristol-Myers Squibb Co.
DescriptionCombination of glipizide and metformin
Molecular Target ATP-dependent potassium channel (KATP)
Mechanism of ActionATP-dependent potassium channel (KATP) blocker
Therapeutic ModalitySmall molecule: Combination
Latest Stage of DevelopmentMarketed
Standard IndicationDiabetes
Indication DetailsTreat Type II diabetes
Regulatory Designation

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today